Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

Table 1 Baseline characteristics and treatment details of patients in the matched cohort, n (%)

Characteristics	Levels	Control group (n = 78)	Experiment group (n = 25)	P value
Age	> 60	33 (42.3)	10 (40)	1.000
	≤ 60	45 (57.7)	15 (60)	-
Gender	Male	48 (61.5)	15 (60)	1.000
	Female	30 (38.5)	10 (40)	-
ECOG	1	75 (96.2)	23 (92)	0.759
	2	3 (3.8)	2 (8)	-
Primary tumor location	Right colon	27 (34.6)	12 (48)	0.335
	Left colon and rectum	51 (65.4)	13 (52)	-
Primary tumor surgery	No	12 (15.4)	3 (12)	1.000
	Yes	66 (84.6)	22 (88)	-
Number of metastatic organs	1	55 (70.5)	19 (76)	0.783
	≥ 2	23 (29.5)	6 (24)	-
Liver metastasis	No	37 (47.4)	9 (36)	0.441
	Yes	41 (52.6)	16 (64)	-
Lung metastasis	No	58 (75.3)	19 (76)	1.000
	Yes	19 (24.7)	6 (24)	-
RAS	Unknown	16 (20.5)	8 (32)	0.496
	Wild-type	15 (19.2)	4 (16)	-
	Mutation	47 (60.3)	13 (52)	-

The control group received chemotherapy combined with bevacizumab. The experimental group received chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy. ECOG: Eastern Cooperative Oncology Group.